Literature DB >> 19773747

Germline bone morphogenesis protein receptor 1A mutation causes colorectal tumorigenesis in hereditary mixed polyposis syndrome.

Peh Yean Cheah1, Yu Hui Wong, Yuk Ping Chau, Carol Loi, Kiat Hon Lim, Jit Fong Lim, Poh Koon Koh, Kong Weng Eu.   

Abstract

OBJECTIVES: Hereditary mixed polyposis syndrome (HMPS) is characterized by polyps of mixed adenomatous/hyperplastic/atypical juvenile histology that are autosomal dominantly inherited and that eventually lead to colorectal cancer (CRC). Although CRC with adenomatous polyps is initiated by inactivating adenomatous polyposis coli (APC), the initiating event of CRC with mixed polyps remains unclear. We aimed to identify the underlying germline defect in HMPS.
METHODS: We screened for bone morphogenesis protein receptor 1A (BMPR1A) mutation by exonic sequencing, reverse-transcriptase polymerase chain reaction (PCR) followed by cDNA sequencing, and multiplex ligation-dependent probe amplification (MLPA) analysis in eight Singapore Chinese HMPS families.
RESULTS: Germline BMPR1A defects were found in four (50%) families. In two families, it is shown to co-segregate with the disease phenotype in all affected members over three generations, indicating that it is the disease-causing mutation. CRC incidence is 75%. The most defining characteristic is the presence of mixed hyperplastic-adenomatous polyps. Juvenile polyps are rarely reported, and if present, are usually of mixed components. Detailed histology of the polyps from one patient over 11 years distinguishes HMPS from juvenile polyposis syndrome (JPS). We report further the first cases of Wilms' tumor and papillary thyroid carcinoma associated with BMPR1A germline defect.
CONCLUSIONS: Germline BMPR1A defect is the disease-causing mutation in 50% of the HMPS families. If patients present with mixed morphology polyps in the large bowel that are autosomal dominantly inherited and corresponding absence of upper gastrointestinal abnormalities, the gene to begin mutation screening should be BMPR1A rather than APC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773747     DOI: 10.1038/ajg.2009.542

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  18 in total

1.  Reply to "The classification of intestinal polyposis".

Authors:  Ian Tomlinson; Emma Jaeger; Simon Leedham; Huw Thomas
Journal:  Nat Genet       Date:  2013-01       Impact factor: 38.330

2.  The classification of intestinal polyposis.

Authors:  Peh Yean Cheah; Kiat Hon Lim; Poh Koon Koh; Choong Leong Tang
Journal:  Nat Genet       Date:  2013-01       Impact factor: 38.330

Review 3.  Next generation sequencing and a new era of medicine.

Authors:  Graham Casey; David Conti; Robert Haile; David Duggan
Journal:  Gut       Date:  2012-05-01       Impact factor: 23.059

4.  Therapy-associated polyposis as a late sequela of cancer treatment.

Authors:  Matthew B Yurgelun; Jason L Hornick; Victoriana K Curry; Chinedu I Ukaegbu; Emily K Brown; Elaine Hiller; Anu Chittenden; Joel E Goldberg; Sapna Syngal
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

5.  Defining the polyposis/colorectal cancer phenotype associated with the Ashkenazi GREM1 duplication: counselling and management recommendations.

Authors:  James Ziai; Ellen Matloff; Jaehyuk Choi; Ninani Kombo; Miguel Materin; Allen E Bale
Journal:  Genet Res (Camb)       Date:  2016-03-07       Impact factor: 1.588

6.  Germline Mutations in the Polyposis-Associated Genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 Are Not Common in Individuals with Serrated Polyposis Syndrome.

Authors:  Mark Clendenning; Joanne P Young; Michael D Walsh; Sonja Woodall; Julie Arnold; Mark Jenkins; Aung Ko Win; John L Hopper; Kevin Sweet; Steven Gallinger; Christophe Rosty; Susan Parry; Daniel D Buchanan
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

Review 7.  Genetics, cytogenetics, and epigenetics of colorectal cancer.

Authors:  Lucia Migliore; Francesca Migheli; Roberto Spisni; Fabio Coppedè
Journal:  J Biomed Biotechnol       Date:  2011-02-14

8.  Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.

Authors:  Abdelaziz Alsamarah; Alecander E LaCuran; Peter Oelschlaeger; Jijun Hao; Yun Luo
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

9.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

Authors:  Heather Hampel; Robin L Bennett; Adam Buchanan; Rachel Pearlman; Georgia L Wiesner
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

10.  Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1.

Authors:  Emma Jaeger; Simon Leedham; Annabelle Lewis; Stefania Segditsas; Martin Becker; Pedro Rodenas Cuadrado; Hayley Davis; Kulvinder Kaur; Karl Heinimann; Kimberley Howarth; James East; Jenny Taylor; Huw Thomas; Ian Tomlinson
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.